14th December 2022
BCI’s Dr Ana Rio-Machin is part of a new research collaboration agreement that will leverage Envisagenics’ SpliceCore® AI platform for expanded discovery and research in haematopoietic cancers.
Read more28th November 2022
Professor Tatjana Crnogorac-Jurcevic and her team at Barts Cancer Institute, Queen Mary University of London, are working to identify biological clues or ‘biomarkers’ for early, non-invasive detection of pancreatic cancer in urine samples. In their most recent paper, published in the International Journal of Cancer, the team reported that a urine biomarker panel could detect pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, up to 2 years before clinical diagnosis.
Read more10th November 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a new channel of communication through which non-cancerous cells drive the invasion of cancer cells in pancreatic cancer. By blocking a particular signalling molecule within this pathway, called Fibroblast Growth Factor Receptor 1, the team was able to reduce invasion of pancreatic cancer cells in the laboratory.
Read more4th November 2022
On 21 October, Research.com released its first annual ranking of top female scientists in the world and Professor Fran Balkwill from Barts Cancer Institute, Queen Mary University of London, has been named as one of the top 100 female scientists in the UK. The aim of the ranking is to “inspire female scholars, women considering an academic career, as well as decision-makers worldwide with the example of successful women in the scientific community.”
Read more17th October 2022
Congratulations to Professor Victoria Sanz-Moreno from Barts Cancer Institute at Queen Mary University of London who has received the Estela Medrano Memorial Award from the Society of Melanoma Research, which honours women who have made major contributions in the fight against melanoma.
Read more12th October 2022
Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London has received a UK Research and Innovation (UKRI) Frontier Research grant of over £2 million to investigate the most effective ways to remodel cancers to enhance the effects of immunotherapy.
Read more